Curis (CRIS) Announces Presentation of Early PK, Biomarker Data from CA-170 Phase 1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/6/2024
- Wall Street rises on growing hopes for Fed rate cuts
- Baird says this name is one of the top chip stocks you should own
- Apple shares dip premarket after Buffett's Berkshire Hathaway cuts stake
- Robinhood receives SEC notice about potential action against crypto unit, shares slip
- World shares climb on Fed cut bets, China gains; yen weakens
- Robinhood (HOOD) receives "Wells Notice" from the Staff of the SEC
- Pfizer (PFE) Appoints Andrew Baum as Chief Strategy and Innovation Officer
- Mullen Automotive, Inc (MULN) Announces Adoption of Limited Duration Stockholder Rights Plan
- Mullen Automotive (MULN) Signs Agreement with California Based and HVIP Approved, National Auto Fleet Group
- Apple shares dip premarket after Buffett's Berkshire Hathaway cuts stake
- Midday movers: Apple slips; Palantir and Micron gain
- Midday movers: Apple, Amgen and Block rise; Cloudflare and Expedia fall
- After-hours movers: Apple, Block, Coinbase, Booking and more
- Midday movers: Carvana and Qualcomm rise; DoorDash, Fastly, Zillow fall
- After-hours movers: Qualcomm, Carvana rise; DoorDash, Etsy, Fastly fall
Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference
November 9, 2016 12:16 PM ESTLEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today presented preliminary clinical pharmacokinetic (PK) and early biomarker data from the ongoing dose escalation stage of CA-170s Phase 1 trial at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs in National Harbor, MD. CA-170 is a potent and selective, orally available small molecule antagonist of the programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T cell activation (VISTA)Â immune checkpoints.
... More
